Akèy › Kansè Glann Salivè › New York
Etid klinik pou Kansè Glann Salivè nan New York
5 etid pou Kansè Glann Salivè ap chèche patisipan nan sit nan New York.
Vil nan New York
Tèks ofisyèl etid la (Anglè)
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Mount Sinai Hospital, New York
- ak 2 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05408845A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT06695845Integrated Cancer Repository for Cancer Research
- C.R. Wood Cancer Center, Glens Falls Hospital, Glens Falls
- Faxton St. Luke's Healthcare, Mohawk Valley, Utica
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
- ak 2 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 13, 2026 · NCT04620187VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Weill Cornell Medicine, Cornell University (site 126), New York
Ap rekriteFaz 1/2
Laj 18 a 80 · Tout sèks · Mizajou Dec 11, 2025 · NCT03556228Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.